For the year ending 2025-12-31, CPMD made $1,362,163 in revenue. -$11,743,745 in net income. Net profit margin of -862.14%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 1,362,163 | 820,137 | ||
| Cost of goods sold | 3,447,071 | 3,755,064 | ||
| Gross loss | -2,084,908 | -2,934,927 | ||
| General and administrative | 489,641 | 116,640 | ||
| Payroll and consulting fees | 0 | - | ||
| Professional fees | 469,690 | 435,511 | ||
| Rent | - | 4,381 | ||
| Payroll and consulting fees | - | 114,798 | ||
| Royalty expense | 303,525 | - | ||
| Total operating expenses | 1,262,856 | 671,330 | ||
| Loss from operations | -3,347,764 | -3,606,257 | ||
| Change in the fair value of derivative conversion feature | -850,152 | - | ||
| Change in the fair value of obligation to issue shares | 1,487,328 | - | ||
| Foreign exchange gain | 66,252 | - | ||
| Interest expense | 1,958,785 | 2,264,095 | ||
| Imputed interest expense | 490,630 | - | ||
| Loss on the extinguishment of debt | 0 | -690,712 | ||
| Loss on impairment of investment | 4,518,127 | - | ||
| Change in the fair value of derivative conversion feature | - | 105,064 | ||
| Gain on write-off of accounts payable and accrued liabilities | 410,430 | - | ||
| Change in the fair value of obligation to issue shares | - | -3,449,789 | ||
| Other expense | 1,930,000 | - | ||
| Total other income (expenses), net | - | -6,299,532 | ||
| Total other expenses | -7,783,684 | - | ||
| Net loss | -11,131,448 | -9,905,789 | ||
| Foreign currency translation adjustment | -612,297 | 591,243 | ||
| Net comprehensive loss | -11,743,745 | -9,314,546 | ||
| Diluted EPS | -0.02 | -0.02 | ||
| Diluted Average Shares | 662,501,405 | 625,276,406 | ||
CANNAPHARMARX, INC. (CPMD)
CANNAPHARMARX, INC. (CPMD)